This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
Published . Updated .
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock soared.
Directly affected
- PPLI People
Named in this report.
- VKTX Viking Therapeutics
Named in this report.
- LLY Eli Lilly
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
Source: MarketWatch
Eli Lilly (LLY) since this story, compared with the market
Since the first closing price after “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month,” Eli Lilly (LLY) is +7.75%. The S&P 500 fund (SPY) is -0.17% over the same days, a +7.92% difference versus the market.
Official trades in Eli Lilly (LLY) around 22 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 7 days after publication, inside 30 days. The filing is listed beside the story “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 11 days before publication, inside 30 days. The filing is listed beside the story “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month.”
- Rohit Khanna buy Eli Lilly (LLY) ($1,001 - $15,000). That is 18 days before publication, inside 30 days. The filing is listed beside the story “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 50 days before publication, inside 60 days. The filing is listed beside the story “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 54 days before publication, inside 60 days. The filing is listed beside the story “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 54 days before publication, inside 60 days. The filing is listed beside the story “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Eli Lilly (LLY)
Companies mentioned with this story
- LLY Eli Lilly
For “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month,” Eli Lilly (LLY) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names ELI LILLY & CO in the summary; GA resolved that company to LLY
- ACHC Acadia Healthcare
For “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
For “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
In “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 22 Sep 2026 story “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month.” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
In “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Eli Lilly (LLY)
The 22 Sep 2026 story “This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month” names Eli Lilly (LLY) because of this story.
What ties Eli Lilly (LLY) to the headline is this: The reported development directly names ELI LILLY & CO in the summary; GA resolved that company to LLY
A second company, Acadia Healthcare (ACHC), is listed for a different reason: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Eli Lilly (LLY)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. LLY traded between 1131.55 and 1275.56 across 20 sessions. The latest close on file is 1240.65.
What the saved facts support for Eli Lilly (LLY)
46 out of 100
“This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.